Cargando…

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

INTRODUCTION: EGFR mutations drive a subset of NSCLC. Patients harboring the common EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect of osimertinib on NSCLC with atypical EGFR mutations is not well desc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Jingran, Aredo, Jacqueline V., Piper-Vallillo, Andrew, Huppert, Laura, Rotow, Julia K., Husain, Hatim, Stewart, Susan, Cobb, Rosemary, Wakelee, Heather A., Blakely, Collin M., Wong, Melisa L., Gubens, Matthew A., Madani, Mohammad H., Digumarthy, Subba R., McCoach, Caroline, Piotrowska, Zofia, Neal, Joel W., Riess, Jonathan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984841/ https://www.ncbi.nlm.nih.gov/pubmed/36879929 http://dx.doi.org/10.1016/j.jtocrr.2022.100459

Ejemplares similares

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
por: McCoach, Caroline E., et al.
Publicado: (2021)

Role of imaging biomarkers in mutation-driven non-small cell lung cancer
por: Mendoza, Dexter P, et al.
Publicado: (2020)

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
por: Blakely, Collin M., et al.
Publicado: (2017)

Using Time-Varying Covariates in Multilevel Growth Models
por: McCoach, D. Betsy, et al.
Publicado: (2010)

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
por: Velazquez, Ana I., et al.
Publicado: (2020)

Testing for intersectional measurement invariance with the alignment method: Evaluation of the 8‐item patient health questionnaire
por: Cintron, Dakota W., et al.
Publicado: (2023)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
por: Banla, Leou Ismael, et al.
Publicado: (2023)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Developing and Applying the Propensity Score to Make Causal Inferences: Variable Selection and Stratification
por: Adelson, Jill L., et al.
Publicado: (2017)

Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia
por: De Silva, Dane A., et al.
Publicado: (2017)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
por: Maynard, Ashley, et al.
Publicado: (2020)

MRI in detection of hepatocellular carcinoma (HCC)
por: Digumarthy, Subba R, et al.
Publicado: (2005)

Evaluation of a National Comprehensive Cancer Network Guidelines–Based Decision Support Tool in Patients With Non–Small Cell Lung Cancer: A Nonrandomized Clinical Trial
por: Wu, Susan Y., et al.
Publicado: (2020)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
por: Ali, Moiez, et al.
Publicado: (2022)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Potential Pitfall in the Assessment of Lung Cancer with FDG-PET/CT: Talc Pleurodesis Causes Intrathoracic Nodal FDG Avidity
por: Wang, Yingbing, et al.
Publicado: (2013)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Systematic Identification of Balanced Transposition Polymorphisms in Saccharomyces cerevisiae
por: Faddah, Dina A., et al.
Publicado: (2009)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q5koft60e4ajahu4jpoe5menna